Samsung will invest in Jaguar Gene Therapy in order to discover innovative technology and achieve global competitiveness in a rapidly growing gene therapy market.
The market for gene therapy is growing at an exceptional rate and global competition is intensifying as gene therapy represents a variety of applications and shows prolonged therapeutic effects.
Jaguar Gene Therapy is a
Jaguar Gene Therapy, with plans to start clinical studies next year, is advancing three investigational AAV-based gene therapies for galactosemia, autism spectrum disorder with a genetic cause, and Type I diabetes.
AAV-based gene replacement therapy is the technique of delivering a therapeutic gene into target cells by using AAV vectors as a delivery platform. Jaguar Gene Therapy has developed a unique manufacturing platform that uses the latest technologies and purification techniques to increase product yields while reducing product impurities. This could play a role in overcoming side effects arising from high dosage, which is generally known as a significant challenge in AAV gene therapy.
Samsung, as a strategic investor, will collaborate on manufacturing and developing assets with Jaguar Gene Therapy.
Gene therapy is a medical approach that introduces genetic materials inside the body's cells in an effort to treat or prevent diseases which cannot be addressed by antibody therapy. Furthermore, a single gene therapy treatment with a prolonged therapeutic effect lasting several years can improve patient convenience compared to multiple shots of antibody treatment within a year.
Many global biotech companies are accelerating their gene therapy programs through investment and acquisitions. According to
With Jaguar Gene Therapy as its initial investment,
Gene therapy selected as
Jaguar Gene Therapy's core tech aims to enhance adeno-associated virus (AAV) capsid purity
Samsung will collaborate on manufacturing and developing assets with Jaguar Gene Therapy as a strategic investor
(C) 2022 Electronic News Publishing, source